Back to top

FDA approves Pfizer’s Ibrance combo for metastatic breast cancer

The Food and Drug Administration said it approved Pfizer’s (PFE) Ibrance in combination with trastuzumab, with or without pertuzumab, and endocrine...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Pfizer Inc. (PFE)